Bristol-myers Squibb Compnay

E. R. Squibb Sons, Inc.

Amit Banerjee

Ramesh N Patel

Laszlo J Szarka

Clyde G McNamee

John K Thottathil

Venkata B Nanduri

John J Venit

Jerome L Moniot

Steven L Goldberg

Robert M Johnston

Sushil K Srivastava

Shankar Swaminathan

David A Lust

David R Kronenthal

Richard P Polniaszek

David J Kucera

William John Winter

Milan N Stojanovic

Purushotham Vemishetti

Chung-Pin H Chen

Yadagiri R Pendri

Jeffrey M Evans

Shaopeng Wang

Zhongping Shi

David B Brzozowski

Ambarish K Singh

Jeffrey T Bien

Maotang X Zhou

Jing Liang

Gerard Crispino

Sunil S Patel

Gerald L Powers

Neal G Anderson

Siva Josyula Prasad

Thomas P Tully

Sushil K Rijhwani

Dhileepkumar Krishnamurty

Yeung Yu Chan

Charles Lewis

Mark Liu

Yeung Y Chan

Milan Stojanovic

Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.

Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.

Enzymatic oxidative deamination process

An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of halohydrins from haloketones. The halohydrin products are particularly useful in the preparation of epoxides, which may be employed as intermediates in the preparation of protease inhibitors such as retroviral protease inhibitors.

Enzymatic reduction method for the preparation of halohydrins

An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of compounds useful as intermediates in the preparation of taxanes.

Enzymatic reduction method for the preparation of compounds useful for

A process is provided for preparing a substantially optically pure phosphonate ester or phosphonate thioester intermediate via an enzymatically catalyzed enantioselective reaction, which intermediate is employed in preparing phosphonosulfonate squalene synthetase inhibitors.

Process for preparing an optically pure intermediate for a

An enzymatic process for the preparation of chiral epoxides, monohydroxy or dihydroxy compounds of formula ##STR1## by the stereoselective epoxidation or hydroxylation of benzopyrans of formula ##STR2## or resolution of compounds of formula ##STR3## The compounds of formula I and II are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.

Method of chiral epoxidation of benzopyran or pyranopyridine derivatives

A process is described for selectively preparing a compound of the formula ##STR1## wherein: R.sup.1 is halogen;

Stereoselective preparation of halophenyl alcohols from ketones

The present invention concerns a process for the stereoselective enzymatic reduction of keto group-containing compounds such as N-(4-(2-chloroacetyl)phenyl)methanesulfonamido to form the corresponding hydroxyl-group containing compound. The process is selective for the D(+) enantiomer and is catalyzed by enzymes such as oxido-reductase or dehydrogense, or by microorganisms such as Hansenula, Rhodococcus, or Norcardia species.

Stereoselective reduction of ketones

Microorganisms or reductases derived therefrom reduce a diketo ester ##STR1## to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers ##STR2## which can be used to prepare antihypercholesterolemic agents such as ##STR3##

Stereoselective microbial or enzymatic reduction of 3,5-dioxo esters to

Growing community of inventors

St. Louis, MO, United States of America

Amit Banerjee